Product News

Share this article:
FDA accepted Amgen's Biolgoics License Application (BLS) for denosumab, an investigation drug seeking indication for the treatment and prevention of postmenopausal osteoporosis in women and treatment and prevention of bone loss in patients undergoing hormone ablation therapy for either prostate or breast cancer.  Last July, IMS Health said denosumab had blockbuster potential, and could net sales over $1 billion.
Share this article:
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.